Welcome to our dedicated page for OMNICELL SEC filings (Ticker: OMCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Omnicell, Inc. filings document financial results, guidance updates, governance matters, and capital-plan items for a Nasdaq-listed healthcare technology company focused on medication management. Form 8-K reports furnish quarterly and annual operating results and record material events such as executive appointments and amendments to bylaws.
Proxy materials describe annual meeting proposals, director elections, executive compensation votes, equity incentive plan authorization, certificate of incorporation amendments, auditor ratification, and related stockholder voting mechanics. These filings also provide formal disclosure around Omnicell’s common stock governance, board oversight, and stockholder rights provisions.
Vanguard Portfolio Management reports beneficial ownership of 3,240,874 shares of Omnicell Inc common stock, representing 7.13% of the class as of 03/31/2026. The filing shows sole voting power over 26,108 shares and sole dispositive power over 3,240,874 shares; transactions and holdings are reported on Schedule 13G and the filing is signed on 04/29/2026.
Omnicell, Inc. reported a strong first quarter of 2026, with total revenues of $309.9 million, up 15% from the first quarter of 2025, driven by connected devices, technical services, SaaS and Expert Services, and consumables. GAAP results improved from a prior-year loss to net income of $11.4 million, or $0.25 per diluted share, while non-GAAP net income rose to $25.0 million, or $0.55 per diluted share. Non-GAAP EBITDA increased to $44.7 million, reflecting better profitability and cost discipline. The company generated $54.5 million of operating cash flow and ended March 31, 2026 with $239.2 million in cash and cash equivalents and $167.9 million of convertible senior notes. Omnicell raised its full year 2026 guidance for non-GAAP EBITDA to $153–$168 million and non-GAAP EPS to $1.80–$2.00, and now expects 2026 total revenues of $1.215–$1.255 billion.
Omnicell, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 19, 2026. Holders of 45,477,299 common shares as of March 27, 2026 may vote online or by proxy.
Stockholders will elect three Class I directors to serve until the 2029 annual meeting, cast an advisory say‑on‑pay vote on named executive officer compensation, and consider an amendment to the 2009 Equity Incentive Plan to add 1,600,000 shares for future equity awards. They will also vote on amending the Amended and Restated Certificate of Incorporation to add Delaware‑permitted officer exculpation and make minor updates, and on ratifying Deloitte & Touche LLP as independent auditor for 2026.
The nine‑member, largely independent board uses a combined CEO/Chairman structure with a Lead Independent Director, formal risk oversight (including cybersecurity), stock ownership guidelines, anti‑hedging and insider‑trading policies, and standing Audit, Compensation, Corporate Governance, and M&A committees. Non‑employee directors receive cash retainers and annual restricted stock awards for board and committee service.
Njoku Nnamdi reported acquisition or exercise transactions in this Form 4 filing.
OMNICELL, INC. Executive Vice President and Chief Operating Officer Nnamdi Njoku received a grant of 46,296 shares of common stock in the form of Restricted Stock Units as equity compensation. The award was granted under the company’s equity incentive plan at no cash cost to him.
One-third of these RSUs will vest on the first anniversary of the April 1, 2026 grant date. The remaining two-thirds will vest in equal installments on the second and third anniversaries. After this grant, Njoku directly holds 161,535.4457 shares of Omnicell common stock.
Manley Corey J reported acquisition or exercise transactions in this Form 4 filing.
OMNICELL, INC. executive Corey J. Manley, EVP & Chief Legal/Admin Officer, received a grant of 25,132 Restricted Stock Units (RSUs) of common stock at a stated price of $0.00 per share, reflecting a compensation-related equity award rather than a market purchase.
According to the award terms, one-third of the RSUs will vest on the first anniversary of the grant date, with the remaining two-thirds vesting in equal installments on the second and third anniversaries. Following this grant, Manley directly holds a total of 121,849.3392 shares of Omnicell common stock, including this new RSU award.
LIPPS RANDALL A reported acquisition or exercise transactions in this Form 4 filing.
OMNICELL, INC. Chairman, President and CEO Randall A. Lipps received a grant of 90,939 shares of Common Stock in the form of restricted stock units at a price of $0.00 per share on 2026-04-01. These RSUs were granted under the company’s equity incentive plan.
According to the vesting schedule, one-third of the RSUs will vest on the first anniversary of the grant date, with the remaining two-thirds vesting in equal installments on the second and third anniversaries. After this grant, Lipps directly holds 535,531.0741 shares of Common Stock.
In addition to his direct holdings, shares are also held indirectly in trusts: 355,861 shares are held in trust with his wife, and 8,051 shares are held in trust for the benefit of his children.
Radford Harlan Baird reported acquisition or exercise transactions in this Form 4 filing.
OMNICELL, INC. reported that EVP & Chief Financial Officer Harlan Baird Radford received a grant of 37,037 shares of Common Stock in the form of Restricted Stock Units under the company’s equity incentive plan. One-third of the RSUs will vest on the first anniversary of the grant date, with the remaining two-thirds vesting in equal installments on the second and third anniversaries. Following this award, Radford directly holds 69,969 shares of Common Stock.
NUTT BRIAN H. reported acquisition or exercise transactions in this Form 4 filing.
OMNICELL, INC. reported that VP and Chief Accounting Officer Brian H. Nutt received a grant of 5,556 shares of common stock in the form of Restricted Stock Units under the company’s equity incentive plan. These RSUs were awarded at no cash cost per share and increase his directly held position to 23,085.6135 shares.
According to the award terms, one-third of the RSUs will vest on the first anniversary of the grant date, and the remaining two-thirds will vest in equal installments on the second and third anniversaries. This structure is typical for long-term incentive compensation designed to retain executives over multiple years.
Omnicell, Inc. Schedule 13G discloses that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared beneficial ownership of 2,288,570 shares of Omnicell common stock, representing 5.0% of the class. The filing is a joint filing and is signed by the reporting parties.
The filing states the shares are held by entities over which reporting persons have voting and investment discretion and provides the reporting persons' addresses and citizenships. Exhibit I is a Joint Filing Agreement dated March 31, 2026.